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sleep in patients with depression: study
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Abstract
Background: Unipolar depression is one of the most important mental disorders. Insomnia is a symptom of cardinal
importance in depression. It increases the risk to develop depression, negatively affects disease trajectory, is the most
common symptom after remission, increases the risk of relapse, and is associated with higher suicide rates. Existing
therapies for insomnia in depression have limitations. Further adjuvant therapies are therefore needed. Acute aerobic
exercise has been shown to have beneficial effects on sleep in healthy individuals and patients with insomnia. We
therefore hypothesize that a single session of aerobic exercise has a positive impact on sleep in patients with unipolar
depression. This trial aims to investigate the effects of a single bout of aerobic exercise on the subsequent night’s sleep
in patients with depression.
Methods/design: This is a two-arm parallel group, randomized, outcome assessor blinded, controlled, superiority trial.
Patients between 18 and 65 years of age with a primary diagnosis of unipolar depression (without a psychotic episode)
are included. Exclusion criteria are regular use of hypnotic agents, opioids, and certain beta-blockers, as well as the
presence of factors precluding exercise, history of epilepsy, restless legs syndrome, moderate obstructive sleep apnea,
and a BMI > 40. The intervention is a single bout of aerobic exercise, performed for 30min on a bicycle ergometer at
80% individual anaerobic threshold. The control group sits and reads for 30min. The primary outcome is sleep efficiency
measured by polysomnography. Secondary outcomes include further polysomnographic variables, subjective pre-sleep
arousal, nocturnal cardiovascular autonomic modulation, subjective sleep quality, daytime sleepiness, and adverse events.
According to the sample size calculation, a total of 92 patients will be randomized using minimization.
Discussion: This trial will add new information to the body of knowledge concerning the treatment of insomnia
in patients with depression. Thereby, the results will inform decision makers on the utility of acute aerobic exercise.
Trial registration: Clinicaltrials.gov, NCT03673397. Protocol version 1 registered on 17 September 2018.
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Background
Unipolar depression is a mental disorder of paramount
importance. Worldwide the lifetime prevalence is esti-
mated to be between 10 and 15% [1]. It is projected to
become the leading cause of burden of disease world-
wide by 2030 [2]. Core symptoms of depression are
depressed mood, anhedonia, and a lack of drive. De-
pression is associated with an increased risk of comor-
bidities [3] and cardiovascular mortality [4]. It is also
associated with lower cardiorespiratory fitness [5], an
independent risk factor for cardiovascular mortality in
healthy individuals [6].
There is a plethora of research concerning treatments
for depression. Psychotherapy, pharmacotherapy or a
combination of both are the primary treatments for
depression according to guidelines [7, 8]. Meta-analytic
data show moderate to large effect sizes for pharma-
cotherapy (0.35), psychotherapy (0.37), and combined
therapy (0.74) when compared to placebo [9]. However,
the STAR*D trial investigating four treatment steps in
over 4000 patients concluded that only two-thirds of
people treated for depression with pharmacotherapy,
cognitive behavioral therapy, or both were in remission
after treatment [10]. Moreover, the majority of patients
tend to prefer non-pharmacological treatments for
insomnia [11, 12] and depression [13]. Hence, there is a
need for further adjuvant non-pharmacological treat-
ment options.
Insomnia encompasses problems initiating or main-
taining sleep with daytime impairments [14]. Another
symptom may be non-restorative sleep. The current
state of knowledge suggests that hyperarousal [15, 16],
as well as sleep reactivity [17], are core etiological factors
of insomnia. Hyperarousal can be cognitive (e.g., rumi-
nation, dysfunctional beliefs), emotional (emotional
reactivity), cortical (beta activity in sleep EEG), or
physiological (e.g., metabolic rate, heart rate variability).
There is an abundance of research related to insomnia
treatments. Cognitive behavioral therapy for insomnia
(CBT-I) and pharmacotherapy are currently considered
first- and second-line therapies for insomnia (regardless
whether comorbidities are present or not) [17, 18]. CBT-I
is very effective [19]. However, the number of trained
specialists considerably limits access to this treatment.
Pharmacologic agents such as benzodiazepines, non-
benzodiazepines, and sedating antidepressants are another,
arguably more frequently administered therapy for insom-
nia. However, pharmacotherapy has multiple limitations:
(1) effects have been shown to be statistically significant
but of limited clinical relevance [20, 21], (2) dosages
and (3) prescription duration frequently exceed re-
commendations of health agencies [22, 23] (especially
in patients with comorbidities [24, 25]), (4) it poten-
tially has severe adverse effects [26–28], and (5) patients
often prefer non-pharmacological therapies [11, 29, 30].
Therefore, there is a need to develop further non-
pharmacological treatments.
Insomnia is a highly relevant symptom of depression.
Depending on the methodological approach, studies have
found 25–90% prevalence rates of insomnia in people with
depression [31, 32]. Longitudinal studies have repeatedly
found a bidirectional link between insomnia and de-
pression [33–36]. Insomnia is of prognostic relevance. It
negatively affects the disease trajectory [37], is the most
frequent residual symptom after treatment response or
remission [31, 38, 39], increases the probability of relapse
[37, 40, 41], and is an independent risk factor for suicide
[42, 43] as well as adverse somatic outcomes, particularly
cardiovascular disease [44]. Insomnia has considerable
economic cost. Individuals who have insomnia are at
higher risk for work presenteeism [45, 46] and absen-
teeism [47] with higher direct costs per short-term ab-
sence [48]. Sleep problems are also associated with more
work injuries [49]. Insomnia increases the risk of ending
employment prematurely [50] and increases the risk of
disability retirement due to depression [51].
Insomnia of depressed individuals has been neglected in
research, despite its known relevance. Until approximately
one decade ago, a central etiological distinction was made
between ‘organic’ and ‘psychogenic’ or ‘primary’ and
‘secondary’ insomnia [52]. However, this distinction has
been challenged because, among other reasons, there is
often a lack of evidence for a mechanistic distinction
between primary and secondary insomnia [52]. There-
fore, a paradigm shift has become apparent, recom-
mending specific treatments for comorbid insomnia.
This paradigm shift might explain why, until recently,
most trials have focused on patients with insomnia
without any comorbidities.
Aerobic exercise is a viable candidate for the treatment
of insomnia in patients for depression. Meta-analyses
have shown a positive impact of acute and chronic
exercise in healthy individuals with small to moderate
effect sizes [53, 54]. Meta-analyses focusing on indivi-
duals with at least mild insomnia but no comorbidities
have found a moderate effect of chronic aerobic exer-
cise on sleep quality [54–56]. Aerobic exercise has
further positive effects such as improving depressive
symptoms [57] and cardiorespiratory fitness [58]. The
latter is especially relevant for the reduction of cardio-
vascular risk [6].
Current sleep hygiene recommendations, which are also
relevant for depression, lack feasibility. In particular, they
state that exercise should not be performed after 2 pm
[59]. This time constraint presents a considerable limi-
tation since many people can only accommodate aerobic
exercise in the late afternoon or evening. Even more so
this may be limiting for patients with morning depression
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who may feel more energetic to exercise in the afternoon
[60]. However, a recent meta-analysis has found equivocal
effects of exercise performed in the afternoon or
evening in healthy individuals [54]. In healthy individ-
uals, effects of a single evening bout of aerobic exer-
cise on nocturnal heart rate variability seem to
depend on intensity, duration, and timing relative to
sleep but do not seem to alter subjective sleep quality
[61, 62]. One trial has investigated the effects of acute
aerobic exercise in chronic primary insomniacs, showing
moderate to large effect sizes for shortened sleep onset
latency, improved sleep efficiency, and longer total
sleep time [63].
Rationale and hypotheses
An extensive literature search yielded no randomized con-
trolled trials investigating the acute effects of exercise on
sleep in patients with depression. Several studies concerned
with chronic effects are available, and we will summarize
these in our upcoming systematic review and network
meta-analysis (PROSPERO ID 115705, registration not
published yet). Considering this gap in the literature and
the uncertainty concerning the effects of exercise per-
formed in the afternoon on sleep in patients with de-
pression, a trial on this topic is of high clinical importance.
We hypothesize that an acute bout of aerobic exercise
improves 1) sleep efficiency [54, 63], 2) sleep continuity
[63], 3) sleep architecture [54], 4) subjective sleep quality
[64], 5) daytime sleepiness [65], 6) nocturnal blood
pressure [66], 7) pre-sleep arousal, and 8) pre- and post-
sleep heart-rate variability. We expect no effect on 9)
nocturnal heart rate variability [62] and 10) the fre-
quency and severity of adverse events [64].
This paper presents the design and protocol for the
trial according to the Standard Protocol Items: Re-
commendations for Interventional Trials (SPIRIT) state-
ment [67] (Additional file 1).
Methods/design
Study design and setting
This study is designed as a two-arm parallel group,
randomized, outcome assessor blinded, controlled trial,
to assess the superiority of (i) an acute bout of aerobic
exercise compared to (ii) control in ameliorating sleep
efficiency in patients with depression (Fig. 1).
The trial is conducted in the psychosomatic inpatient
rehabilitation unit of the OBERWAID AG, a rehabi-
litation clinic in St. Gallen, Switzerland. Patients are
referred to the clinic by their general practitioner or a
psychiatrist. On average, approximately 250 patients
with a primary diagnosis of an ICD-10 depressive epi-
sode without psychotic features are referred to the clinic
annually. The OBERWAID AG also offers outpatient
psychosomatic care, cardiovascular inpatient rehabili-
tation, and orthopedic aftercare.
Participants
Eligibility criteria
Patients aged 18–65 years with a diagnosis of depression
(confirmed by experienced psychiatrists according to
ICD-10) undergoing inpatient psychosomatic rehabili-
tation in the OBERWAID clinic are eligible for inclusion.
Fig. 1 Trial design
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Further inclusion and exclusion criteria with corres-
ponding rationales are listed in Table 1.
Recruitment
Patients are given the study information at the preliminary
medical consultation, which takes place approximately 3
weeks (but no later than 2 days) before admission. On the
day of admission, the clinical trial is presented to the
patients by the study coordinator. Patients who are inter-
ested in participating in the study can ask the study co-
ordinator questions directly. In order to ensure adequate
time to consider their participation, interested and poten-
tially eligible patients meet the study coordinator for an
informed discussion again on the following day (i.e.,
the first day after admission). The study coordinator
obtains the written informed consent from patients willing
to participate. Should the study coordinator be absent, his
designated replacement obtains the informed consent.
The information sheet and consent form are in Ger-
man (Additional file 2). It is clinical routine for the
leading physicians to give all patients a general con-
sent form.
Retention
Appointments for data collection are included in the
therapy schedule during the first 6 days of rehabilitation,
which should reduce the burden on patients and ensure
protocol fidelity. We give patients feedback on their
measurements. We will send a digital copy of publi-
cations based on this trial to participants if they have
chosen to receive one. No monetary compensation is
offered for participation.
Withdrawal, discontinuation, and stopping rules
Participants can withdraw from the trial at any time
without having to provide reasons. If possible, we collect
follow-up data and reasons for withdrawal. Patients can
be withdrawn from the trial by the principal investigator
for medical reasons (e.g., transfer to another hospital).
Exercise testing and training is immediately stopped,
should any indications for exercise test termination, as
defined by the American College of Sports Medicine, be
met [69]. In this case, we collect follow-up data if there
are no contraindications.
Measurements and procedure
Rationale for measurements
This section offers a rationale for the selected variables
and performed measurements. Details of each assess-
ment (measurement variable, reliability, validity, analysis
metric, method of aggregation, time point, and clinical
relevance) are provided below.
Baseline This trial does not exclude patients with
psychiatric comorbidities in order to preserve external
validity. Therefore, we perform an extensive baseline
characterization of the sample (Fig. 2). The
characterization consists of questionnaires on psychi-
atric, somatic, and insomnia-specific symptom severity
as well as sleep-related variables such as chronotype
and sleep-related cognitions. Furthermore, baseline
Table 1 Inclusion and exclusion criteria
Criterion Rationale
Inclusion criteria
≥ 18 and≤ 65 years old Results of the trial should be
generalizable to the working age
population. Furthermore, there can
be numerous reasons for sleep
disorders in older patients [68]
Primary diagnosis of depression
(F32, F33) without psychotic
episode according to ICD-10
Mental disorder used to define the
sample
Exclusion criteria
Regular use of hypnotic agents*
(patients are included if no
hypnotic agents were taken two
weeks before study
participation)
Use of hypnotic agents might
mask the effect of aerobic exercise
on sleep
Factors precluding exercise
testing or training
For safety reasons, patients who
have any condition which
precludes exercise testing or
training are excluded. Absolute
and relative contraindications are
based on ACSM’s Guidelines for
Exercise Testing and Prescription [69]
Use of beta-blockers
(except carvedilol and nebivolol)
Except for carvedilol and nebivolol
[70, 71], beta-blockers have been
shown to reduce nocturnal
melatonin levels [70, 72, 73]
Use of opioids Opioids affect sleep architecture [74]
History of epilepsy Epilepsy is associated with
quantitative and qualitative
alterations of sleep [75] and might,
therefore, mask the intervention
effects
Restless legs syndrome defined
by ≥ 7 points on the restless
legs screening questionnaire [76]
Can also cause sleep disturbance,
but the etiology is distinct from
depression [77]
Moderate or severe sleep apnea
defined by an oxygen
desaturation index (ODI) ≥ 15 in
the first polysomnography
Sleep apnea is a distinct sleep
disorder with clearly delineated
etiology. ODI has been shown to
be highly correlated with the
apnea-hypopnea index and to
detect sleep apnea with high
sensitivity and specificity [78–80]
Morbid adiposity with BMI > 40 These patients might suffer from
hypoventilation syndrome which
affects sleep
ICD-10 International Classification of Diseases, version 10, ODI oxygen
desaturation index, BMI body mass index
*Hypnotic agents are defined as follows: orexin receptor agonists,
benzodiazepine receptor agonists, sedating antidepressants, neuroleptics,
benzodiazepines, melatonin agonists, heterocyclics, anticonvulsants, over the
counter sleep aids (sedating antihistamines, melatonin L-tryptophan, valerian),
and cannabinoids
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polysomnography will provide an extensive
characterization of sleep.
Primary outcome Sleep disorders are of complex
etiology and have various psycho-physiological
consequences. Therefore, it is recommended to
measure the effects of interventions on insomnia
symptoms as well as other factors such as daytime
functioning and mood [81]. Insomnia can be classi-
fied into sleep-onset, sleep-maintenance, and sleep-offset
Fig. 2 Participant timeline - Spirit figure
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subtypes. Meta-analysis of polysomnographic data has
shown that patients with depression and other mental
health disorders have mixed (i.e., sleep-onset and sleep-
maintenance) insomnia [82]. Sleep efficiency best captures
both of these aspects and is therefore chosen as the primary
outcome. Objective quantification of the primary outcome
is vital in this study since the blinding of participants is not
possible, thereby potentially affecting subjective
measurements.
Secondary outcomes Secondary outcomes which in-
form clinical decision making include further poly-
somnographic variables, subjective pre-sleep arousal,
cardiovascular autonomic modulation, subjective sleep
quality, daytime sleepiness, and adverse events. Wake
after sleep onset and number of awakenings identify
sleep-maintenance insomnia, while sleep-onset latency
characterizes sleep-onset insomnia.
Patients with depression show characteristic changes
in rapid eye movement (REM) latency (time between
sleep onset and first rapid eye movement sleep episode),
REM-density (frequency of rapid eye movements/REM
episode), and duration of REM sleep (collectively known
as REM pressure) [82]. More importantly, these alter-
ations have a negative impact on treatment and increase
the risk of relapse [83]. Exercise has been shown to
reduce REM sleep and increase slow wave sleep [54].
The discrepancy between objective and subjective sleep
measurements is well documented [81, 84, 85]. There-
fore, we measure the subjective sleep quality of the pre-
vious night in addition to the objective sleep assessment.
Patient views influence the treatment of sleep disorders
[86, 87]. Hence, it is crucial to ascertain the credibility of
the intervention and the expectancy of participants.
Adverse events are underreported in sleep trials but
highly relevant to clinical decision making [88]. The case
report form specifically captures adverse events (see
below) to gauge the benefit to harm ratio.
Screening
After providing informed consent, we formally screen
patients for inclusion and exclusion criteria of this study.
They are consulted by an experienced psychiatrist and
undergo a full history and medical examination by an
experienced internist, including vital parameters. (Resting
electrocardiogram may be forgone if the general prac-
titioner of the patient provides one no older than 2
months.) Patients with undiagnosed sleep apnea are
excluded according to the baseline polysomnography
(see below).
Graded exercise testing
Patients fulfilling all eligibility criteria (except the sleep
apnea criterion, which is determined later by
polysomnography) undergo sub-maximal graded exercise
testing on a bicycle ergometer (ergoselect 200, Ergoline,
Bitz, Germany). The goal is to determine the individual
anaerobic threshold. The anaerobic threshold is used to
standardize the exercise intensity of the intervention
across patients. Since subjects vary in their endurance
capacity and weight, we adjust initial and subsequent work
rates (Watts) between subjects before the test. Stage dur-
ation is always 3 minutes, as this has been found to yield
the most reliable and valid results [89]. We measure blood
lactate at the end of each stage using capillary blood from
the earlobe. We assess blood lactate level with Lactate
Scout+ (SensLab GmbH, Leipzig, Germany), a validated
hand-held analyzer [90]. Heart rate is measured using the
validated Polar® H7 chest strap (Polar OY, Finland) [91].
Parasympathetic drive is still present at lower exercise
intensities and thus increases heart rate variability [92].
The average heart rate during the last 30 s of each stage is
extracted to improve precision and used for further
analyses. Ratings of perceived exertion are recorded at the
end of each stage according to Borg’s 6–20 scale [93]. The
graded exercise test data are analyzed using a specialized
software program (Ergonizer, Freiburg, Germany). The
individual anaerobic threshold is determined according to
the method of Dickhuth et al. [94].
Baseline characterization of symptom severity
To characterize the study population in detail, we will re-
port multiple continuous measures at baseline as median
with corresponding interquartile range or frequencies.
Somatic and psychological symptom severity In accor-
dance with the International Consortium for Health
Outcomes Measurement (ICHOM) Depression and
Anxiety working group, depression symptoms are
assessed with the German version of the Patient Health
Questionnaire-9 (PHQ-9) including the additional ques-
tion on functioning [95]. The nine symptom items are
scored on a four-point Likert scale (not at all to nearly
every day; Cronbach’s α = 0.89). The cut-offs of the aggre-
gated sum score have been validated and allow for classi-
fication of mild to severe depression [96]. Anxiety is
assessed using the Hospital Anxiety and Depression Scale.
This questionnaire measures depression and anxiety with
seven items each on a four-point Likert scale [97]. A
meta-analysis has found Cronbach’s α to be 0.83 and 0.82
for the anxiety and depression subscales, respectively [98].
Diagnostic test accuracy of the depression and anxiety
subscale is high [99]. More recently, a meta confirmatory
factor analysis has suggested the presence of a general dis-
tress factor explaining most of the covariance between
items [100]. The German version has been shown to have
adequate psychometric properties [101]. We measure
stress with the German version of the ten-item Perceived
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Stress Scale, which has demonstrated good reliability
(Cronbach’s α = 0.84) and validity [102]. Therein, stress is
operationalized as the degree to which life is experienced
as unpredictable, uncontrollable, and overloaded in the
past months on a five-point Likert scale (never to very
often). Somatic multimorbidity is measured using the
self-administered Patient Health Questionnaire Somatic
Symptom Scale (PHQ-15), which has good reliability
(Cronbach’s α = 0.8) and validity [103]. This question-
naire measures the presence and severity of somatic
symptoms during the past 4 weeks on a three-point
Likert scale (not bothered at all to bothered a lot). The
items assess symptoms clusters which account for more
than 90% of physical complaints reported in out-patient
settings [103]. Lastly, the German version of the Modified
Cumulative Illness Rating Scale provides physician-rated
scores of multimorbidity. This scale has a good inter-rater
agreement and concurrent and predictive validity. It
measures the presence and severity multimorbidity over
14 organ systems on a five-point scale (no problem to
extremely severe problem) [104].
Subjective measurements related to sleep Multiple
sleep-related variables are measured to characterize the
impact of sleep disorders in the population. The German
version of the Pittsburgh Sleep Quality Index [105] is
used to quantify subjective sleep disturbance. This 18
item scale assesses subjective sleep quality, sleep latency,
sleep duration, habitual sleep efficiency, sleep dis-
turbances, use of sleeping medication, and daytime
dysfunction. It has adequate psychometric properties
(Cronbach’s α = 0.83) [106]. The corresponding global
score with a cut-off value of ≥ 5 has been shown to
distinguish good and poor sleepers [107]. We measure
sleep reactivity, i.e., the degree to which an individual
experiences disrupted sleep due to stress, with the
Ford Insomnia Response to Stress Test [108, 109].
The nine-item self-report questionnaire is answered
on a four-point Likert scale (not very likely to very
likely) with higher total scores indicating a higher
likelihood of stress-induced insomnia. The reliability
(Cronbach’s α = 0.80) and validity of the German version
have been demonstrated [110]. Dysfunctional sleep-related
thoughts and attitudes are related to the development and
trajectory of sleep disorders [111]. The reliability and vali-
dity of the German short form of the dysfunctional beliefs
and attitudes about sleep scale have recently been de-
monstrated (average Cronbach’s α = 0.71) [112]. Sixteen
items measure four domains (consequences, worry/help-
lessness, expectations, medication) on a ten-point Likert
scale (strongly disagree to strongly agree). Excessive day-
time sleepiness is associated with insomnia and depres-
sion [113, 114] as well as reduced quality of life and
work performance [115]. We assess chronic daytime
sleepiness using the German version of the Epworth
Sleepiness Scale. This questionnaire has good reliability
(Cronbach’s α 0.83 in patients) and validity [116]. The like-
lihood of dozing off in eight daily situations (e.g., sitting
and reading) is assessed on a four-point Likert scale
(would never doze to high chance of dozing). Chronotype,
i.e., peak alertness throughout the day, is associated with
more severe depression, insomnia, and suicidality in
patients with major depression. Furthermore, eveningness
substantially increased the risk of non-remission inde-
pendently of insomnia severity [117]. The Morningness-
Eveningness Questionnaire assesses chronotype with 19
multiple-choice questions (four- or five-point scale) on
sleep habits and propensity for performance throughout
the day. The sum ranges from 16 to 86 and can be trans-
lated into chronotypes (< 42, evening type; 42–58, neither;
> 58, morning type) [118]. Criterion validity has been
established [119]. Validity and reliability (test-retest
reliability > 0.96) have been confirmed for the German
version [120].
Polysomnography (baseline and follow-up)
Polysomnography is considered the gold standard of
sleep assessment [121]. However, one significant draw-
back of this method is the so-called first-night effect.
This effect describes altered sleep patterns due to novel
environments, disturbances by measurement equipment,
a potential Hawthorne effect, or a combination thereof
[122]. Such alterations typically represent worse sleep
quality, e.g., reduced sleep efficiency, in the first com-
pared to the second night [122]. Although this effect has
been found in different patient groups, it is clearly atte-
nuated in individuals with depression [123–125]. More-
over, polysomnographic measurements are expensive
and performing multiple measurements is not always
feasible. Several authors argue that data from the first
night (i.e., baseline) should, therefore, be used in the
analyses [123, 125]. In designs where baseline and follow-
up data are collected, analysis of covariance (ANCOVA)
has multiple advantages. Firstly, there is less potential for
bias compared to the analysis of change (i.e., pre minus
post) scores or follow-up data only. Secondly, ANCOVA
has higher statistical power [126, 127].
Montage Polysomnography is performed with the
SOMNOscreen™ plus RC (Somnomedics, Randersacker,
Germany) using the following montage: one EEG channel
(Fp2-A1, 512Hz), two EOG channels (1 cm below and 1
cm lateral of the outer right canthus as well as 1 cm above
and 1 cm lateral of the outer left outer canthus, 512Hz),
one EMG channel (Chin1-Chin2, 512Hz), one ECG
channel (modified lead II, 512Hz), thoracic respiratory
effort channel (inductance plethysmography belt, 32 Hz),
finger photoplethysmography (non-dominant arm, 128Hz),
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body position (stored every 30 s), movement (32Hz), and
ambient light (stored every 30 s). Relevant skin areas are
prepared with Nuprep (Weaver & Co., Aurora, CO, USA)
before electrode placement to reduce skin impedance. Al-
though this montage does not comply with AASM stan-
dards [128], the use of a single channel EEG, two EOG
channels, and one EMG channel has been shown to have
good validity when assessing sleep stages [129].
Analysis of polysomnography We apply low- and high-
frequency filters according to AASM guidelines [128].
Oxygen desaturation index (ODI) is defined as the
number of oxygen desaturations (≥ 4%) measured by
photoplethysmography per hour of total sleep time
[128]. We analyze polysomnography data visually in
epochs of 30 s by two trained, independent, and
blinded raters according to AASM guidelines [128]. If
sleep efficiency differs by ≤ 5% between raters, we use
the mean of each quantitative sleep parameter of both
raters for analysis. If sleep efficiency differs by > 5%
between raters, a consensus scoring is done by a third
rater who is blinded against allocation and previous
ratings. Inter-rater reliability (intraclass correlation)
based on the scoring of the first two raters will be
provided for the primary outcome. Sleep parameters
are calculated with the proprietary DOMINO software
(Somnomedics, Randersacker, Germany) (Table 2).
Sleep parameters can be grouped into three domains:
1. Sleep continuity: high sleep efficiency, low sleep
onset latency, low wake after onset, low number of
awakenings
2. Sleep depth: less stage 1 and 2 sleep, more stage 3
(i.e., slow wave) sleep
3. REM pressure: low REM latency, more REM sleep,
(high REM-density)
Nocturnal autonomic cardiovascular modulation Sleep
hygiene recommendations include daily exercise. Two
caveats of this recommendation are that exercise should
be performed before 2 pm and that no strenuous exercise
ought to be done close to bedtime. One reason for this
recommendation is that exercise in the afternoon or
evening might increase arousal and thereby prevent sleep
[59]. However, evidence from numerous epidemiological,
observational, and experimental studies have repeatedly
failed to show such an adverse effect or have found that
the opposite is true [54, 130]. The issue of nocturnal
autonomic modulation following exercise is of central
importance for three reasons. Firstly, arousal is integral to
one of the most widely accepted etiological theories of
insomnia [15, 16]. Secondly, heart rate variability (HRV),
as a marker of autonomic arousal, has been proposed as a
potential pathophysiological mechanism linking depres-
sive disorders [131, 132] and insomnia [133] with car-
diovascular disease. Thirdly, nocturnal blood pressure and
nocturnal blood pressure dipping are of prognostic rele-
vance for cardiovascular disease [134]. Therefore, sleep
quality, as well as nocturnal autonomic activity, should be
assessed when evaluating interventions in sleep research.
Measurements of heart rate, HRV, and pulse transit time
(and thereby calculated blood pressure) are collected to
quantify the effect of exercise on parameters of autonomic
cardiovascular arousal.
We record the ECG while subjects are lying in bed.
Patients were instructed to lie in the supine position and
refrain from speaking as well as moving during the two
short-term (i.e., 5-minute) recordings. No instructions
concerning breathing were given. All ECG measure-
ments were sampled at 512 Hz using modified lead II.
Three sections of HRV data are analyzed:
1. A short-term pre-sleep measurement with a duration
of 5 min, beginning after lights off, is taken to
quantify pre-sleep autonomic modulation.
Measurements in which patients have fallen asleep
are excluded from the analysis.
2. A nocturnal 6-h segment beginning after sleep
onset. We choose this definition of the nocturnal
HRV assessment for multiple reasons. According
Table 2 Sleep parameters
Sleep parameter Definition
Total recording
time (TRT)
Time between the lights-off and
lights-on markers (min)
Total sleep time (TST) Time asleep (in any sleep stage)
within TRT (min)
TST = N1 + N2 + N3 + REM
Sleep onset
latency (SOL)
Time between lights-off marker
and first epoch of any sleep stage
Wake after sleep
onset (WASO)
Time awake after first sleep episode (min)
WASO = TRT - SL - TST
Number of
awakenings (NA)
Number of wake periods of at least
two epochs after sleep onset
Sleep efficiency (SE) Percentage of sleep while in bed (%)
SE = (TST / TRT) × 100
N1 Stage 1 (in minutes and % TST)
N2 Stage 2 (in minutes and % TST)
N3 Stage 3 (in minutes and % TST)
Light sleep Stage 1 and 2 (in minutes and % TST)
NREM (non-REM) sleep Stage 1–3 (in minutes and % TST)
REM Rapid eye movement (in minutes and % TST)
REMLAT Time between sleep onset and the
occurrence of the first REM sleep epoch (min)
Stage shift index Number of transitions between any wake
or sleep stage/hours of sleep
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to guidelines, durations of recordings have to be
of equal length [135]. Nocturnal measurement
segments of 4 or 6 h are frequently used in studies
[136, 137]. In such trials, the starting point of the
measurement period is usually defined by either
sleep onset (identified by EEG or sleep diary) or
a fixed time (e.g., 00:00). Since sleep onset is
associated with increased parasympathetic
modulation [138], we use sleep onset defined by
polysomnography to mark the starting point of the
segment to be analyzed. Using this starting point
avoids potential bias which might be introduced by
inter-individual differences in sleep onset latency
and chronotype when using a fixed time. We chose a
6-h segment as it offers a more extended measurement
period than 4 h. Moreover, 6 h is commonly
considered the cut-off for objective short sleep
duration [139, 140] and thus can be understood
as a minimum sleep requirement for most
individuals. Nocturnal HRV is dynamic, as
non-REM sleep (primarily during the first half
of the night) and REM sleep (primarily during
the second half of the night) are characterized by
parasympathetic and sympathetic predominance,
respectively [138, 141]. We split the 6-h period
into hourly segments, which allows the dynamic
mentioned above to be partially captured.
3. A short-term post-sleep segment of 5 min beginning
after the last awakening and before standing up to
quantify post-sleep autonomic modulation. Patients
are instructed to lie supine in bed after awakening
for 5 min (using a timer). The post-sleep
measurement has the advantage of limiting
external factors which influence HRV.
The time- and frequency-domain measures which we
calculate are described in Table 3. Low (LF) and high
frequency (HF) power in normalized units (LFnu and
HFnu) will not be reported. The rationale for this
deviation from guidelines is that LFnu, HFnu, and LF/HF
ratio have been shown to carry algebraically and therefore
physiologically redundant information [142, 144]. Report-
ing of data collection, analysis, cleaning, and calculation
will follow the GRAPH guidelines [145]. The percentage
of beats identified as artifacts will be reported for both
groups for each segment (median and inter-quartile
range). Measurements with > 5% artifacts will be excluded
from analysis.
An ongoing debate in the literature concerns the
choice of method for spectral analysis. Fast Fourier
transform (FFT) using Welch’s periodogram and auto-
regressive modeling (AR) seem to be the most frequently
used methods for power spectral analysis [135, 143].
Another method to estimate power spectral density is the
Lomb-Scargle periodogram (LSP) [146, 147]. LSP has
numerous advantages when compared to FFT and AR.
LSP is designed to estimate the power density spectrum
directly from the unevenly sampled tachogram. AR and
FFT, on the other hand, need to be interpolated and
resampled to fulfill the prerequisite of evenly sampled
data. Resampling leads to over- and under-estimation of
LF and HF, respectively [148, 149]. FFT and AR require a
Table 3 HRV parameters
Method Measure of variability Calculation of variable Physiological mechanism
Time-domain methods
Statistical RMSSD Root mean square of successive
differences of NN intervals
Short-term components of HRV,
vagal modulation
SDNN Standard deviation of the of all
NN intervals
Overall HRV, cyclic components
responsible for HRV
SDANN Standard deviation of the averages
of NN intervals in all 5-min segments
of the entire recording (only for
nocturnal HRV)
Long-term components of HRV
Frequency domain methods
Lomb-Scargle Periodogram
and
Fast Fourier transformation
TP Total power: power density spectrum
in the frequency range of 0.00001
to 0.4 Hz [ms2]
Overall HRV
LF Low-frequency power: power density
spectrum in the frequency range
of 0.04 to 0.15 Hz [ms2]
Sympathetic and vagal activity,
baroreflex activity (vasomotor tone)
HF High-frequency power: power density
spectrum in the frequency range
of 0.15 to 0.40 Hz [ms2]
Vagal modulation
LF/HF Ratio LF [ms2]/HF [ms2] Sympathetic and vagal modulation
Calculations are based on [135, 142]. Descriptions of physiological mechanisms are based on [142, 143]
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trade-off between frequency resolution and time re-
solution (statistical stability) when choosing window
length [150] and model order [151], respectively. In con-
trast, LSP makes no assumptions of models. Investigations
have shown that LSP is more accurate [152–154], is less
noisy [154], has higher reliability [155], and is more sensi-
tive to physiological changes [155–157] when compared
to FFT. Consequently, multiple authors have suggested
LSP as the method of choice for spectrum analysis of
HRV [152, 158]. For these reasons, we estimate power
spectral density using LSP smoothed with a moving
average filter (width 0.02Hz) in this trial. To enable
comparison with other studies, we also calculate Welch’s
FFT and will report it as a sensitivity analysis.
We perform ECG pre-processing and HRV analysis
using Kubios HRV (University of Eastern Finland, Kuopio,
Finland) [159]. This software has been shown to have
perfect intra-class correlation coefficients (ICC = 1.000)
across HRV variables measured during different postures
when compared to two other software [120]. QRS de-
tection is based on the Pan-Tompkins algorithm [160],
including bandpass filtering. Beat detection is visually
inspected. Erroneously detected RR fiducial points are
corrected by manual editing of R-wave. Artifacts are iden-
tified using the automatic artifact correction algorithm
[161]. This algorithm has been shown to detect ectopic
beats with an accuracy of 97%. Ectopic beats are replaced
by phantom beats using cubic spline interpolated RR
values. Correction of aberrant RR intervals using cubic
spline interpolation has been shown to perform as well as
other correction methods for frequency analysis [162].
Detrending, i.e., removal of slow-trend and non-linear
trend components is performed using the smoothness
priors approach [163] with λ = 500 and fc = 0.035 Hz (thus
not affecting the lower band of LF). Frequency-domain
variables estimated by LSP are based on de-trended RR
series. Frequency-domain variables estimated by FFT with
Welch’s periodogram are based on de-trended as well as
interpolated (i.e., resampled) RR series. We employ the
following parameters for power spectral density esti-
mation using FFT. RR series are resampled to obtain an
evenly sampled time series using a cubic spline
interpolation with a rate of 4 Hz. A Hann window with a
width of 60 s and 50% overlap is used (corresponding to
240 samples). These window parameters are chosen to
balance the requirement of stationarity and frequency
resolution resulting in an average of 9 and 119 FFT spectra
for 5 min and hourly segments, respectively, with a
frequency resolution of 0.025 Hz. Singh et al. [150] have
shown that these approximate parameters produce a good
spectral estimate (smooth with clear peaks).
Pulse transit time is calculated using ECG and pulse
waveform from photoplethysmography. Blood pressure
(BP) is calculated using the pulse transit time. This method
has been validated [164] according to the European Society
of Hypertension International Protocol (ESH-IP) revision
2010 criteria [165]. Accordingly, we perform a single
initial calibration measurement (manual cuff-based
method, contralateral arm of photoplethysmography,
sitting position). Two significant advantages of this
method are the continuous measurement of BP and
elimination of cuff inflations. The latter is poorly tolerated
by patients, causes awakenings, and may affect the validity
of BP measurements [166]. BP levels differ between non-
REM and REM sleep [167]. Therefore, mean systolic,
mean diastolic, and mean arterial pressures will be
reported separately for total sleep time, non-REM
sleep, and REM sleep.
Subjective sleep-related measurements
Subjective pre-sleep arousal has been shown to be
increased in primary insomnia [168] and seems to
partially mediate the relationship between depressive
symptoms and daytime fatigue [169]. We use the German
version of the Pre-Sleep Arousal Scale to assess cognitive
and somatic pre-sleep arousal. Eight and seven items load
onto the factors somatic (Cronbach’s α = 0.80) and cognitive
(Cronbach’s α = 0.94) arousal, respectively [170]. Items are
scored on a five-point Likert scale (not at all to extremely)
and summed up for each factor separately.
We measure subjective sleep quality of the baseline and
post-intervention night using the revised Schlaffragebogen
A, as recommended by guidelines [171]. Twenty-five items
load onto five factors: sleep quality, recuperation after
sleep, calmness before sleep, exhaustion before sleep,
and psychosomatic symptoms during sleep. Internal
consistency, factor structure, and validity have been
demonstrated in numerous populations [172].
The clinical relevance of excessive daytime sleepiness is
highlighted above (cf. rationale for ESS questionnaire).
State sleepiness is recorded four times (0800, 1200, 1600,
2000 h) on the day after the experimental condition to
gauge the effects on daytime somnolence. The Stanford
Sleepiness Scale is a single item questionnaire assessing
the degree of momentary sleepiness on a seven-point
scale [173]. Adequate psychometric properties have
been demonstrated [174].
Expectancy and credibility
Insomnia treatment guidelines stress the importance of
contextual factors such as patient preference and satis-
faction when choosing the most suitable therapy [88, 175].
Credibility can increase expectancy [176]. The latter has
been shown to influence outcomes in depression and
other disorders [177]. Since patients cannot be blinded in
exercise studies, it is especially important to consider
expectancy. We assess credibility and expectancy on day
three (i.e., before randomization) using two items (adapted
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from [178, 179]): “At this point, how logical does the
therapy offered to you seem?”, “At this point, how
successfully do you think this treatment will be in re-
ducing your insomnia symptoms?”. Patients rate these
items on a four-point Likert scale (not at all to very).
Randomization and blinding
A non-deterministic minimization algorithm is used to
assign interventions. Allocation to intervention or control
group is done using the open source software for online
minimization (Oxford Minimization and Randomization,
OxMaR) [180]. All necessary data for minimization is
collected using surveys integrated into the eCRF. The re-
quired data are entered in the web-based randomization
software by the study nurses. Upon confirmation that the
data are correct, the study participant is allocated to a
group, the allocation is saved in a central database, and an
e-mail containing the allocation is sent to the PI, the study
coordinator, and to the person submitting the participant.
Allocation concealment consists of four aspects: (1)
requesting randomization after baseline measurement, (2)
use of a random element, (3) requesting allocation for
participants by two different study nurses, and (4) not
disclosing full details of minimization to study nurses in
accordance with the SPIRIT guideline [67]. We will
publish a detailed description of the minimization scheme
with the results of the trial.
It is impossible to blind participants in exercise trials.
However, we prevent detection bias though objective
sleep measures which are assessed by two blinded and
independent assessors. Blinding is ensured by replacing
the subject ID with a second unique ID number. The list
matching these IDs is not accessible to the raters.
Intervention and control condition
Aerobic exercise (intervention) Patients allocated to
the intervention group perform a single bout of super-
vised aerobic exercise. The starting time is approxi-
mately 1645 h. The exercise mode is a bicycle ergometer
(ergoselect 200, Ergoline, Bitz, Germany). After a warm-
up period of 5 min, during which the intensity is gra-
dually increased, patients maintain an intensity of 80%
of the individual anaerobic threshold for 30 min. The
intensity level is chosen based on clinical experience that
this corresponds to an approximate rate of perceived
exertion of 13 (on a scale from 6 to 20) in this popu-
lation. The duration of exercise corresponds to physical
activity recommendations [181].
Control condition At the same time as individuals
performing the exercise intervention, individuals
allocated to the control group are placed in a room
which is comparable to that of the exercise group
concerning light, temperature, and absence of music.
The control group is asked to remain seated and
read magazines.
The rules and schedules of the inpatient rehabilitation
clinic (e.g., timing of meals, consumption of multimedia,
and alcohol) limit the variability of many behavioral
aspects which could influence sleep. Occasional smokers
are asked to refrain from smoking after dinner on the
days of polysomnographic assessment. Chronic smokers
are not asked to abstain from smoking as this might be
an additional stressor.
Adherence and other outcomes of interest We assess
the implementation of the intervention with continuous
measurement of Watts and heart rate using a Polar® H7
chest strap (Polar OY, Finland). We measure heart rate
throughout the intervention period, including 3 min
post-exercise. We measure perceived exertion using the
Borg scale (6–20) [93]. All subjects complete a question-
naire on their current mood immediately before and at
the end of the control condition as well as the exercise
intervention. The Befindlichkeitsskala has adequate
psychometric properties [182] and is considerably more
economical than other comparable measures [183]. The
questionnaire consists of 40 items on a five-point Likert
scale (not at all to very much). Items load onto eight
subscales (with five items each): activity (Cronbach’s
α = 0.82), elation (Cronbach’s α = 0.81), contemplation
(Cronbach’s α = 0.70), calmness (Cronbach’s α = 0.78),
fatigue (Cronbach’s α = 0.88), depression (Cronbach’s
α = 0.80), anger (Cronbach’s α = 0.86), and excitement
(Cronbach’s α = 0.73) [182]. Contamination through
any or additional physical activity (depending on the
allocation) is assessed using a wrist-worn accelerometer
(on non-dominant hand) on the days prior to and after
the sleep assessments. The wrist-worn accelerometer
vivofit®2 (Garmin, Schaffhausen, Switzerland) validly
assesses steps in various walking conditions [184].
Although adequate blinding cannot be achieved by design
in exercise studies, this allows for a partial assessment of
performance bias.
Concomitant, ancillary, and post-trial care The trial
takes place in the first 5 days of the patient’s psychosomatic
in-patient rehabilitation. The rehabilitation programme
entails different therapies, including exercise therapy.
Patients included in the study are asked to refrain
from exercise except as defined by the protocol on
the days of testing. Patients are explicitly made aware
of this aspect before enrollment. Ancillary and post-
trial care is provided throughout the in-patient re-
habilitation program, i.e., on average for 4 weeks after
completion of the study.
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Adverse events We assess adverse events through a
questionnaire. We ask patients in both groups whether
they experience adverse effects on a five-point Likert
scale (not at all to very) using the following categories
immediately after the intervention and the following
morning:
 Pain (if yes, location)
 Dizziness
 Cardiovascular symptoms (e.g., angina symptoms,
cyanosis, pallor)
 Respiratory symptoms (e.g., wheezing)
 Nausea
 Falls (yes or no)
 Other (to be described)
Unplanned termination of participants and the reasons
thereof (if participant proactively gives one) will also be
reported.
Data management
Data collection
We use castor electronic data capture software for data
collection and data management [185]. This software
complies with Good Clinical Practice guidelines and the
European Data Protection Directive. A unique numeric
subject ID is assigned to each participant to conceal the
identity of participants in the database. The file which
links the numeric subject ID to the participant infor-
mation is kept in a password-protected folder in an
encrypted digital file and on paper in a locked cabinet.
These digital and paper files are exclusively stored at the
study site. Only the study nurses, the study coordinator,
and the principal investigator have access to this in-
formation. Regulatory agencies (i.e., ethics committee)
will also be granted access upon request. Patient data
are collected using electronic case report forms (eCRF).
Range and dependency checks are implemented into the
eCRF and completeness checks of data for each partici-
pant are performed during the trial. The eCRF can be
found in Additional file 3. All study personnel have been
trained in measurement procedures and data collection
according to the case report form using standard opera-
ting procedures to ensure standardized data collection.
Data from the polysomnography are uploaded to the
CASTOR platform using the subject ID to match data.
Security, storage, and access
Study nurses, the study coordinator, the principal investi-
gator, and monitors can access the password-protected
database. The principal investigator and study co-
ordinator define user accounts and user rights accor-
ding to their responsibilities, e.g., authorization for
data changes. All changes in the eCRF are saved in
data trails, audit trials, and edit trails, (including reasons
for changes). The data are stored for 15 years. The study
coordinator and principal investigator will have full access
to the trial data.
Data monitoring and audits
Due to the risk stratification of this trial, the need for a
data-monitoring committee is waived. Central data
monitoring is performed using the built-in modules of
the CASTOR software. No interim analyses are planned.
Monitoring of regulatory files, study processes, and data
is conducted in four visits: before enrollment of the first
patient, after enrollment of the first patient, after enroll-
ment of 50% of patients, and after last patient last visit.
Monitoring is done by the Clinical Trial Unit, Basel,
Switzerland (i.e., an organization independent from the
investigator and sponsor).
Statistical methods
Sample size calculation
The theoretical rationale for the analysis of the primary
outcome, using an ANCOVA model, is outlined above
(see the “Polysomnography (baseline and follow-up)” sec-
tion). Furthermore, minimization necessitates adjustment
for minimization factors [186]. Sample size calculation
was performed according to the procedure defined by
Borm et al. [187]. The allocation ratio is 1:1. The expected
treatment effect is based on the work of Passos et al. [63],
who found a standardized mean difference in sleep effi-
ciency of 0.53. The estimate is based on this publication
because it is the only one known to the authors which (1)
evaluated the acute effect of (2) a similar intervention (i.e.,
moderate aerobic exercise) (3) in individuals with sleep
disorders. Due to the well-documented ceiling and floor
effects [188], meta-analyses concerning predominantly
healthy individuals (explicitly excluding individuals with
mental disorders) [54] are of no use. Meta-analyses
including individuals with sleep complaints are limited
to the analysis of the chronic effects of exercise on
sleep [55, 189]. With a power of 0.8 and a two-sided
alpha of 0.05, 57 subjects would be required for each
group using a t-test. According to the method of Borm et
al., this sample size can be multiplied by a ‘design factor’
of (1 − ρ2), where ρ is the correlation coefficient between
baseline and follow-up outcome [187]. Despite contacting
other researchers, the authors are not aware of any pre-
vious study which have analyzed this aspect. Hence, we
need to make an estimate. Recommended values for im-
putation of ρ vary between 0.5 (if variances are equal at
pre- and post-measurements, ρ is at least 0.5) and
0.7 [190, 191]. We use a conservative estimate and
let ρ = 0.5. This leads to a design factor of 0.75 (1 − 0.52 =
0.75). Hence, the sample size needed per group is 43 (57 ×
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0.75 = 42.75). Due to the short-term nature of this study,
we expect approximately half the dropout rate of trials
investigating the chronic effects of exercise in patients
with depression [192]. Thus, we anticipate 7% dropouts.
Therefore, the total sample size is 92 (2 × 43 × 1.07 = 92).
Analysis of the primary outcome
The main aim of this trial is to analyze the acute effect of
aerobic exercise on the subsequent night’s sleep efficiency
measured by polysomnography. To this end, we will com-
pute a one-way ANCOVA with baseline sleep efficiency
and minimization factors as covariates, intervention as the
independent variable, and post-exercise sleep efficiency as
the dependent variable. Clinical significance will be de-
termined using the criteria defined in the American
Academy of Sleep Medicine Clinical Practice guideline for
the Pharmacological Treatment of Chronic Insomnia in
adults. Thereby, an absolute change in sleep efficiency of
≥ 5% is deemed clinically relevant. We define responders
as individuals who have an increase in sleep efficiency of
≥ 5% from baseline to post-intervention. We will report
the number, the proportion, and the odds ratio of
responders as well as the number needed to treat. In order
to reduce attrition bias to a minimum, all analyses will
follow the intention-to-treat framework.
Sensitivity analyses for the primary outcome will be
performed to gauge the influence of several factors: out-
liers (defined as < Quartile 1 − 1.5 × Interquartile range;
> Quartile 3 + 1.5 × Interquartile range), per-protocol
analysis (to reflect optimal adherence to treatment),
missing data (analysis of complete data only), excluding
minimization factors (age, sex, PHQ-9 score, and
Pittsburgh Sleep Quality Index score), chronotypes,
smoking status, and use of beta-blockers. We will report
all results of sensitivity analyses. We will replace missing
data using multiple imputation with the mi package in R
[193]. The quantity of missing data will be reported.
Analysis of secondary outcomes
Secondary outcomes will also be analyzed using ANCOVA
models when variables have been assessed at baseline
and follow-up. Hourly segments of nocturnal HRV
will be analyzed using a linear mixed model with
subject as random effect, adjusting for baseline and
minimization factors. Acute daytime sleepiness will be
assessed using repeated measures ANOVA with
Benjamini-Hochberg [194] corrected post hoc paired
sample t-tests. Measurements where only post-intervention
group-comparisons are possible will be analyzed using
t-tests. The threshold for statistical significance is set
at p < 0.05. The authors point out that the secondary
analyses are not adjusted for multiple testing and are
of exploratory nature.
Ethics and dissemination
Ethics approval
The Ethics Committee East Switzerland, St. Gallen,
Switzerland, has approved the study (EKOS 18/089). We
registered the trial with the ClinicalTrials.gov database
(NCT03673397) on September 17, 2018. No protocol
amendments have been made. Approval for any potential
future amendments will be obtained from the local
ethics committee.
Dissemination policy
We will disseminate trial results to all stakeholders, e.g.,
participants (if they choose to receive these at enroll-
ment), physicians, and study nurses. Results will be
published in a peer-reviewed journal and presented at
conferences as well as invited talks. Authorship on peer-
reviewed publications will be based on contributions
toward design, fundraising, data collection, analysis, and
manuscript preparation. De-identified (i.e., coded) in-
dividual participant data that underlie the results of
published articles, including data dictionaries, will be
available upon request under the creative commons
license CC-BY. Requests will only be granted for use in
individual participant data meta-analysis which has been
approved by an independent review committee. Excep-
tions to these rules are reserved within the context of
peer-reviewed publications, provided that data integrity
remains intact. Data will be provided upon request
immediately after publication of peer-reviewed articles
with no end date. Requests should be sent to the e-mail
address detailed in the following Dataverse repository
(https://doi.org/10.7910/DVN/WASN36).
Discussion
The goal of this two-arm parallel group, individually
randomized, single-blind, controlled trial is to assess the
superiority of an acute bout of aerobic exercise com-
pared to no intervention in improving the subsequent
night’s sleep efficiency in patients with a primary diagno-
sis of depression. To the knowledge of the authors, this
is the first trial to investigate the acute effects of exercise
on sleep in this population.
The main strength of this study is the objective measure-
ment of sleep. Moreover, multiple secondary outcomes
were carefully selected to provide clinicians, patients, and
policy makers with a comprehensive picture of the effects
this intervention may have. Explicit inclusion of patients
with comorbidities should enhance the external validity of
this study. Accordingly, we provide extensive baseline
characterization.
The main limitation of this trial is the restricted poly-
somnographic EEG montage. More detailed analyses,
such as spectral EEG analysis, will therefore not be
possible. Extensive discussions in our research group
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resulted in an explicit trade-off between the patients’
discomfort (number of EEG channels) and feasibility of
recruitment. The restricted EEG montage will help to
recruit the necessary number of patients in an adequate
period in this clinical setting. The pre-selection of
patients who are treated in this rehabilitation clinic
might pose a further limitation. Extensive baseline
characterization will help readers identify limits to
external validity. Patients cannot be blinded against
allocation in exercise trials. We try to overcome this
limitation through various measures (see above).
There is compelling evidence for the effectiveness of
various therapies for both insomnia and depression.
Nevertheless, many of these therapies have shortcom-
ings. Development of further therapeutic options, which
can be administered in addition to these therapies, are
therefore needed. Current literature suggests that acute
aerobic exercise might improve both depression and
insomnia. Although chronic aerobic exercise is included
in sleep hygiene recommendations, there is uncertainty
concerning the acute effects of aerobic exercise on sleep
in patients with depression. This trial aims to close this
gap in the literature as well as to help the increasing
number of patients with depression.
Trial status
We registered this trial on September 17, 2018, in the
ClinicalTrials.gov database (NCT03673397). All items of
the World Health Organization Trial Registration Data
Set can be found in the ClinicalTrials.gov registration.
This is the first version of the protocol, i.e., we have
made no amendments. Recruitment began on September
24, 2018. Recruitment is expected to be completed by
October 2019.
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